- ICH GCP
- US Clinical Trials Registry
- Klinisk forsøg NCT06906341
Relacorilant i kombination med nab-paclitaxel og bevacizumab i avanceret, epitelial ovarie, primær peritoneal eller æggelør kræft
En fase 2-undersøgelse af relacorilant i kombination med nab-paclitaxel og bevacizumab i avanceret, epitelial ovarie, primær peritoneal eller æggelørkræft (Bella)
This is a Phase 2, open-label, global, multi-arm study to evaluate efficacy and safety of relacorilant in combination with other treatments in patients with gynecological cancers.
Studieoversigt
Status
Intervention / Behandling
Detaljeret beskrivelse
This study is designed with the goal to add additional arms as new treatments become available. All arms will follow an independent and parallel design.
For Arms A and B, study treatment will comprise relacorilant combined with nab-paclitaxel, and bevacizumab and will begin on Cycle 1 Day 1 (C1D1). Each patient will receive relacorilant 150 mg administered orally under fed conditions, once daily for 3 consecutive days on the day before, the day of, and the day after nab-paclitaxel infusion (in Cycle 1 relacorilant is only given on 2 consecutive days, starting on C1D1), in combination with nab-paclitaxel (80 mg/m^2 intravenously [IV]) administered on Days 1, 8, and 15 of each 28-day cycle. Bevacizumab (10 mg/kg IV once every 2 weeks [Q2W]) will be administered on Days 1 and 15 of each 28-day cycle. Study treatment for Arm C will be similar to Arm A but does not include bevacizumab. Patients will receive treatment until they reach a protocol-defined event of progressive disease (PD), experience an unmanageable toxicity, or until other treatment discontinuation criteria are met.
Undersøgelsestype
Tilmelding (Anslået)
Fase
- Fase 2
Kontakter og lokationer
Studiekontakt
- Navn: Corcept Therapeutics
- Telefonnummer: 650-414-2314
- E-mail: corceptstudy557@corcept.com
Studiesteder
-
-
-
Brussels, Belgien, 1200
- Rekruttering
- 109
-
Charleroi, Belgien, 6000
- Rekruttering
- 326
-
Hasselt, Belgien, 3500
- Rekruttering
- 325
-
Leuven, Belgien, 3000
- Rekruttering
- 108
-
-
Belgium
-
Aalst, Belgium, Belgien, 9300
- Rekruttering
- 328
-
-
-
-
Alabama
-
Birmingham, Alabama, Forenede Stater, 35233
- Rekruttering
- 004
-
-
California
-
Palo Alto, California, Forenede Stater, 94304
- Rekruttering
- 150
-
San Francisco, California, Forenede Stater, 94109
- Rekruttering
- 278
-
San Francisco, California, Forenede Stater, 94143
- Rekruttering
- 014
-
-
Colorado
-
Aurora, Colorado, Forenede Stater, 80045
- Rekruttering
- 032
-
-
Florida
-
Fort Myers, Florida, Forenede Stater, 33901
- Rekruttering
- 544
-
Miami Beach, Florida, Forenede Stater, 33140
- Rekruttering
- 335
-
West Palm Beach, Florida, Forenede Stater, 33041
- Rekruttering
- 543
-
-
Illinois
-
Chicago, Illinois, Forenede Stater, 60637
- Rekruttering
- 001
-
-
Minnesota
-
Minneapolis, Minnesota, Forenede Stater, 55404
- Rekruttering
- 518
-
-
Missouri
-
Kansas City, Missouri, Forenede Stater, 64132
- Rekruttering
- 334
-
St Louis, Missouri, Forenede Stater, 63110
- Rekruttering
- 521
-
-
New Mexico
-
Albuquerque, New Mexico, Forenede Stater, 97102
- Rekruttering
- 292
-
-
Ohio
-
Centerville, Ohio, Forenede Stater, 45459
- Rekruttering
- 304
-
-
Oregon
-
Eugene, Oregon, Forenede Stater, 97401
- Rekruttering
- 517
-
-
Pennsylvania
-
Pittsburgh, Pennsylvania, Forenede Stater, 15213
- Rekruttering
- 127
-
-
Virginia
-
Fairfax, Virginia, Forenede Stater, 22031
- Rekruttering
- 522
-
Norfolk, Virginia, Forenede Stater, 23502
- Rekruttering
- 300
-
-
Wisconsin
-
Milwaukee, Wisconsin, Forenede Stater, 53226
- Rekruttering
- 121
-
-
-
-
-
Lille, Frankrig, 59000
- Rekruttering
- 306
-
Nancy, Frankrig, 54100
- Rekruttering
- 307
-
Nice, Frankrig, 06100
- Rekruttering
- 310
-
Pierre-Bénite, Frankrig, 69495
- Rekruttering
- 324
-
Plérin, Frankrig, 22190
- Rekruttering
- 323
-
Toulouse, Frankrig, 31059
- Rekruttering
- 308
-
-
-
-
-
Catania, Italien, 95126
- Rekruttering
- 321
-
Milan, Italien, 20141
- Rekruttering
- 122
-
Milan, Italien, 20159
- Rekruttering
- 516
-
Pavia, Italien, 27100
- Rekruttering
- 295
-
Rome, Italien, 00168
- Rekruttering
- 124
-
Torino, Italien, 10128
- Rekruttering
- 293
-
Treviso, Italien, 31100
- Rekruttering
- 319
-
-
-
-
-
Gdynia, Polen, 81-519
- Rekruttering
- 341
-
Siedlce, Polen, 08-MO
- Rekruttering
- 329
-
-
-
-
-
Badalona, Spanien, 08916
- Rekruttering
- 349
-
Barcelona, Spanien, 08035
- Rekruttering
- 115
-
Madrid, Spanien, 28034
- Rekruttering
- 114
-
Valencia, Spanien, 46026
- Rekruttering
- 330
-
Valencia, Spanien, 46010
- Rekruttering
- 558
-
-
-
-
Gangnam-gu
-
Seoul, Gangnam-gu, Sydkorea, 06351
- Rekruttering
- 396
-
-
Goyang-si
-
Gyeonggi-do, Goyang-si, Sydkorea, 10408
- Rekruttering
- 397
-
-
Jongno-gu
-
Seoul, Jongno-gu, Sydkorea, 03080
- Rekruttering
- 399
-
-
Seocho-gu
-
Seoul, Seocho-gu, Sydkorea, 06591
- Rekruttering
- 523
-
-
Seodaemun-gu
-
Seoul, Seodaemun-gu, Sydkorea, 03722
- Rekruttering
- 398
-
-
Songpa-gu
-
Seoul, Songpa-gu, Sydkorea, 05505
- Rekruttering
- 403
-
-
-
-
-
Aachen, Tyskland, 52074
- Rekruttering
- 519
-
Berlin, Tyskland, 10117
- Rekruttering
- 255
-
Kempten, Tyskland, 87439
- Rekruttering
- 520
-
-
Deltagelseskriterier
Berettigelseskriterier
Aldre berettiget til at studere
Tager imod sunde frivillige
Køn, der er berettiget til at studere
Beskrivelse
Inclusion Criteria:
Arms A and B
- Histologic diagnosis of epithelial ovarian, primary peritoneal, or fallopian-tube carcinoma
- Arm A Only: Platinum-resistant disease
- Arm B Only: Platinum-sensitive disease who had progression while receiving treatment with a poly(ADP-ribose) polymerase (PARP) inhibitor
- Life expectancy of ≥3 months
- Eastern Cooperative Oncology Group (ECOG) performance status 0 or 1
- Able to swallow and retain oral medication
- 1 to 3 lines of prior systemic anticancer therapy
- Adequate organ function
- Negative pregnancy test for patients of childbearing potential
Arm C
- Stage III or IV, recurrent, or metastatic endometrial cancer
- Life expectancy of ≥3 months
- ECOG performance status of 0 or 1
- Able to swallow and retain oral medication
- Prior treatment with a platinum agent and an approved anti-Programmed Cell Death Ligand 1 (PD[L]1) antibody
- 1 to 2 lines of prior systemic anticancer therapy for endometrial cancer
- Must consent to provide an available formalin-fixed paraffin-embedded (FFPE) tumor tissue block or recently cut sections
- Adequate organ function
- Negative pregnancy test for patients of childbearing potential
Exclusion Criteria:
Arm A and B
- Arm A Only: Has progressed while receiving weekly paclitaxel or nab-paclitaxel
- Prior enrollment in a clinical trial of relacorilant
- Prior anticancer therapy related toxicities not resolved to grade ≤1
- Any surgery within 4 weeks prior to enrollment
- Wide-field radiation to more than 25% of marrow-bearing areas
- Medical conditions requiring chronic or frequent treatment with corticosteroids
- Concurrent treatment with mifepristone or other glucocorticoid receptor modulators
- Peripheral neuropathy from any cause >Grade 1
- Hypertension: ≥150 mm Hg systolic or ≥100 mm Hg diastolic
- Uncontrolled condition(s) which, may confound the results of the trial or interfere with the patient's safety or participation
- Bowel obstruction ≤12 weeks prior to study entry
- Ascites or pleural effusions requiring therapeutic paracentesis
- Untreated or symptomatic central nervous system metastases
- History of other malignancy within 3 years prior to enrollment
- Has received a live vaccine within 30 days prior to the study start date
Arm C
- Has progressed while receiving weekly paclitaxel or nab-paclitaxel
- Prior enrollment in a clinical trial of relacorilant
- Prior anticancer therapy related toxicities not resolved to grade ≤1
- Any surgery within 4 weeks prior to enrollment
- Wide-field radiation to more than 25% of marrow-bearing areas
- Medical conditions requiring chronic or frequent treatment with corticosteroids
- Concurrent treatment with mifepristone or other glucocorticoid receptor modulators
- Peripheral neuropathy from any cause >Grade 1
- Uncontrolled condition(s) which, may confound the results of the trial or interfere with the patient's safety or participation
- Bowel obstruction ≤12 weeks prior to study entry
- Ascites or pleural effusions requiring therapeutic paracentesis
- History of other malignancy within 3 years prior to enrollment
- Has received a live vaccine within 30 days prior to the study start date
- Patients with central nervous system metastases are not eligible, unless they have completed local therapy and have discontinued the use of corticosteroids for this indication for at least 4 weeks before starting treatment in this study.
Studieplan
Hvordan er undersøgelsen tilrettelagt?
Design detaljer
- Primært formål: Behandling
- Tildeling: Ikke-randomiseret
- Interventionel model: Parallel tildeling
- Maskning: Ingen (Åben etiket)
Våben og indgreb
Deltagergruppe / Arm |
Intervention / Behandling |
|---|---|
|
Eksperimentel: Arm A: Relacorilant in Combination with Nab-paclitaxel and Bevacizumab
In Arm A, patients with platinum-resistant ovarian cancer will receive the combination of relacorilant with nab-paclitaxel and bevacizumab. |
Relacorilant is administered under fed conditions as capsules for oral dosing on the day before, the day of, and the day after nab-paclitaxel infusion.
Andre navne:
Nab-paclitaxel is administered as IV infusion on Days 1, 8, and 15 of each 28-day cycle. Bevacizumab is administered as IV infusion on Days 1 and 15. |
|
Eksperimentel: Arm B: Relacorilant in Combination with Nab-Paclitaxel and Bevacizumab
In Arm B, patients with platinum-sensitive ovarian cancer who have progressed while receiving treatment with a polymerase inhibitor will receive relacorilant in combination with nab-paclitaxel and bevacizumab. |
Relacorilant is administered under fed conditions as capsules for oral dosing on the day before, the day of, and the day after nab-paclitaxel infusion.
Andre navne:
Nab-paclitaxel is administered as IV infusion on Days 1, 8, and 15 of each 28-day cycle. Bevacizumab is administered as IV infusion on Days 1 and 15. |
|
Eksperimentel: Arm C: Relacorilant in Combination with Nab-Paclitaxel
In Arm C, patients with previously-treated advanced, recurrent, or metastatic endometrial cancer will receive relacorilant in combination with nab-paclitaxel. |
Relacorilant is administered under fed conditions as capsules for oral dosing on the day before, the day of, and the day after nab-paclitaxel infusion.
Andre navne:
Nab-paclitaxel is administered as IV infusion on Days 1, 8, and 15 of each 28-day cycle. |
Hvad måler undersøgelsen?
Primære resultatmål
Resultatmål |
Foranstaltningsbeskrivelse |
Tidsramme |
|---|---|---|
|
Progression-Free Survival (PFS)
Tidsramme: Date of first dose until PD or death, up to 18 months
|
To evaluate PFS as the time from enrollment until first documented progressive disease (PD) by Response Evaluation Criteria in Solid Tumors (RECIST) version 1.1 as determined by the Investigator, or death due to any cause, whichever occurs first. |
Date of first dose until PD or death, up to 18 months
|
Sekundære resultatmål
Resultatmål |
Foranstaltningsbeskrivelse |
Tidsramme |
|---|---|---|
|
Antal patienter med en eller flere bivirkninger
Tidsramme: Dato for den første dosis op til 30 dage efter sidste dosis
|
Dato for den første dosis op til 30 dage efter sidste dosis
|
|
|
Objective Response Rate (ORR)
Tidsramme: Date of first dose until PD or death, up to 18 months
|
To evaluate the proportion of patients with measurable disease at Baseline who attain complete response (CR) or partial response (PR) by RECIST version 1.1. |
Date of first dose until PD or death, up to 18 months
|
|
Best Overall Response Rate (BOR)
Tidsramme: Date of first dose until PD or death, up to 18 months
|
To evaluate the BOR by RECIST version 1.1 recorded from the date of enrollment until PD or death. |
Date of first dose until PD or death, up to 18 months
|
|
Duration of Response (DOR)
Tidsramme: Time of first objective response until PD or death, up to 18 months
|
To evaluate DOR as the time from the first CR or PR to first objectively documented PD or death, whichever comes first. |
Time of first objective response until PD or death, up to 18 months
|
|
Clinical Benefit Rate (CBR)
Tidsramme: Week 24
|
To evaluate CBR as the proportion of patients who attain CR, PR, or stable disease (SD) at Week 24 as per RECIST version 1.1. |
Week 24
|
|
Overall Survival (OS)
Tidsramme: Date of first dose up to 6, 12, and 18 months
|
To evaluate the probability of OS survival at 6, 12, and 18 months. |
Date of first dose up to 6, 12, and 18 months
|
|
Area under the plasma concentration-time curve (AUC) of relacorilant
Tidsramme: On Cycle 1 Day 8 (each cycle is 28 days)
|
To estimate exposure of relacorilant. This outcome applies to Arms B and C only. |
On Cycle 1 Day 8 (each cycle is 28 days)
|
|
Maximum plasma concentration (Cmax) of relacorilant
Tidsramme: On Cycle1 Day 8 (each cycle is 28 days)
|
To estimate exposure of relacorilant. This outcome applies to Arms B and C only. |
On Cycle1 Day 8 (each cycle is 28 days)
|
|
Trough plasma concentrations (Cmin) of relacorilant
Tidsramme: On Cycle 2 Day 8 through the last cycle (up to 12 cycles, each cycle is 28 days)
|
To estimate exposure of relacorilant. This outcome applies to Arms B and C only. |
On Cycle 2 Day 8 through the last cycle (up to 12 cycles, each cycle is 28 days)
|
Samarbejdspartnere og efterforskere
Sponsor
Efterforskere
- Studieleder: Danny Nguyen, MD, Corcept Therapeutics
Datoer for undersøgelser
Studer store datoer
Studiestart (Faktiske)
Primær færdiggørelse (Anslået)
Studieafslutning (Anslået)
Datoer for studieregistrering
Først indsendt
Først indsendt, der opfyldte QC-kriterier
Først opslået (Faktiske)
Opdateringer af undersøgelsesjournaler
Sidste opdatering sendt (Faktiske)
Sidste opdatering indsendt, der opfyldte kvalitetskontrolkriterier
Sidst verificeret
Mere information
Begreber relateret til denne undersøgelse
Nøgleord
- Neoplasmer
- Bevacizumab
- Ovariale neoplasmer
- Paclitaxel
- Relacorilant
- Nab-paclitaxel
- Ovarie
- Neoplasmer efter sted
- Endometrie
- Høj karakter
- Ovariesygdomme
- Genitale neoplasmer, kvindelige
- Peritoneale neoplasmer
- Æggelederneoplasmer
- Platin resistent
- Endometrial neoplasma
- Æggeledersygdomme
- Albumin-bundet Paclitaxel
- Peritoneal eller avanceret æggeleder kræft
- Bella
Yderligere relevante MeSH-vilkår
- Urogenitale sygdomme
- Genitale sygdomme
- Sygdomme i det endokrine system
- Urogenitale neoplasmer
- Urogenitale sygdomme hos kvinder
- Kvinders urogenitale sygdomme og graviditetskomplikationer
- Neoplasmer i fordøjelsessystemet
- Sygdomme i fordøjelsessystemet
- Livmodersygdomme
- Kønssygdomme, kvindelige
- Neoplasmer i endokrine kirtler
- Adnexale sygdomme
- Gonadale lidelser
- Uterine neoplasmer
- Peritoneale sygdomme
- Abdominale neoplasmer
- Neoplasmer
- Ovariale neoplasmer
- Endometriale neoplasmer
- Genitale neoplasmer, kvindelige
- Peritoneale neoplasmer
- Æggelederneoplasmer
- Neoplasmer efter sted
- Ovariesygdomme
- Æggeledersygdomme
- Aminosyrer, peptider og proteiner
- Proteiner
- Antistoffer, monoklonal, humaniseret
- Antistoffer, monoklonal
- Antistoffer
- Immunoglobuliner
- Immunoproteiner
- Blodproteiner
- Serum globuliner
- Globuliner
- Bevacizumab
- 130-nm albuminbundet paclitaxel
- Relacorilant
Andre undersøgelses-id-numre
- CORT125134-557
Plan for individuelle deltagerdata (IPD)
Planlægger du at dele individuelle deltagerdata (IPD)?
Lægemiddel- og udstyrsoplysninger, undersøgelsesdokumenter
Studerer et amerikansk FDA-reguleret lægemiddelprodukt
Studerer et amerikansk FDA-reguleret enhedsprodukt
produkt fremstillet i og eksporteret fra U.S.A.
Disse oplysninger blev hentet direkte fra webstedet clinicaltrials.gov uden ændringer. Hvis du har nogen anmodninger om at ændre, fjerne eller opdatere dine undersøgelsesoplysninger, bedes du kontakte register@clinicaltrials.gov. Så snart en ændring er implementeret på clinicaltrials.gov, vil denne også blive opdateret automatisk på vores hjemmeside .